What's in Infant Bacterial Therapeutics's pipeline?

Infant Bacterial Therapeutics has 1 drugs in our index: 0 marketed, 0 filed, 1 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Infant Bacterial Therapeutics's portfolio?

Top competitors by shared drug class: Ardeypharm GmbH, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Mikrobiomik Healthcare Company S.L., OxThera, Rebiotix Inc..

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/infant-bacterial-therapeutics.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Infant Bacterial Therapeutics — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Infant Bacterial Therapeutics pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
IBP-9414	IBP-9414	phase 3	Live biotherapeutic product		Immunology / Infectious Disease / Pediatrics

Therapeutic area mix

Immunology / Infectious Disease / Pediatrics · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Ardeypharm GmbH · 1 shared drug class
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · 1 shared drug class
Mikrobiomik Healthcare Company S.L. · 1 shared drug class
OxThera · 1 shared drug class
Rebiotix Inc. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Infant Bacterial Therapeutics:

Cite this brief

Drug Landscape (2026). Infant Bacterial Therapeutics — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/infant-bacterial-therapeutics. Accessed 2026-05-16.